48 pages. (9.6.2021). New benzodiazepines, which are not controlled by international drug laws, come under the spotlight in a new report released today. Often marketed as ‘designer benzodiazepines’, these substances are sold as ‘legal’ replacements for controlled benzodiazepines and are becoming increasingly available in Europe. They are monitored by the EMCDDA as new psychoactive substances through the EU Early Warning System (EWS). The report aims to strengthen situational awareness of new benzodiazepines in Europe, their toxicity and abuse potential, and to help stakeholders prepare for, and respond to, public health and social threats caused by such substances.
